Market Cap 24.94M
Revenue (ttm) 500,000.00
Net Income (ttm) -39.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,966.00%
Debt to Equity Ratio 0.00
Volume 84,508
Avg Vol 126,566
Day's Range N/A - N/A
Shares Out 15.21M
Stochastic %K 33%
Beta 1.37
Analysts Strong Sell
Price Target $7.44

Latest News on VYNE

VYNE Therapeutics to Participate in March Investor Conferences

Feb 20, 2025, 8:00 AM EST - 6 weeks ago

VYNE Therapeutics to Participate in March Investor Conferences


Menlo Ventures Raises $1.35B for AI Investments

Nov 16, 2023, 4:03 PM EST - 1 year ago

Menlo Ventures Raises $1.35B for AI Investments


VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:05 AM EDT - 1 year ago

VYNE Therapeutics Announces Private Placement of $88 Million


VYNE Therapeutics to Attend BIO International Convention

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention


VYNE Therapeutics Announces Reverse Stock Split

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split


VYNE Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2022 Financial Results